The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes

References

• Burchenal J. H., Holmberg E. A. D., Fox J. J., Hemphill S. C., Reppert J. A. The effects of 5-fluorodeoxycytidine, 5-fluorodeoxyuridine, and related com pounds on transplanted mouse leukemias. Cancer Research 1959; 19: 494–500
   Google Scholar
• Ford C. H. J., Casson A. G. Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview. Cancer Chemotherapy and Pharmacology 1986; 17: 197–208
   Google Scholar
• Gregoriadis G., Senior J., Wolff B., Kirby C. Targeting of liposomes to accessible cells in vivo. Annals of the New York Academy of Sciences 1985; 446: 319–340
   PubMed Web of Science ®Google Scholar
• Hartmann H. R., Matter A. Antiproliferative action of a novel fluorinated uridine analog, 5′-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines. Cancer Research 1982; 42: 2412–2415
   PubMed Web of Science ®Google Scholar
• Heidelberger C., Griesbach L., Cruz O., Schnitzer R. J., Grunbeg E. Fluorinated pyrimidines: VI. Effects of 5-fluorouridine and 5′-fluoro-2′-deoxyuridine on transplanted tumors. Proceedings of the Society for Experimental Biology and Medicine 1958; 97: 470–475
   PubMed Web of Science ®Google Scholar
• Houghton J. A., Houghton P. J., Wooten R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro 2′-deoxyuridine. Cancer Research 1979; 39: 2406–2413
   PubMed Web of Science ®Google Scholar
• Jansons V. K., Weis P., Chen T., Redwood W. R. In vitro interaction of L1210 cells with phospholipid vesicles. Cancer Research 1978; 38: 531–535
   Google Scholar
• Juliano R., Lopez-Berenstein G., Metha R., Hopfer R., Mehta K., Kasi L. Pharmacokinetic and therapeutic consequences of liposomal drug delivery: Flu orodeoxyuridine and amphotericin B as examples. Biology of the Cell 1983; 47: 39–46
   Google Scholar
• Kawaguchi T., Suzuki Y., Nakahara Y., Nambu N., Nagai T. Activity of esterase in the hydrolysis of 3′,5′-diesters of 5-fluoro-2′-deoxyuridine in relation to the structure of the diester prodrugs. Chemical and Pharmaceutical Bulletin (Tokyo) 1985; 33: 301–307
   PubMed Web of Science ®Google Scholar
• Keizer H. J., PiNedo H. M. Cancer chemotherapy: alternative routes of drug administration. A review. Cancer Drug Delivery 1985; 2: 147–169
   Google Scholar
• Milsmann M. H. W., Schwendener R. A., Weder H. G. The preparation of large single bilayer liposomes by a fast and controlled dialysis. Biochimica et Biophysica Acta 1978; 512: 147–155
   PubMed Web of Science ®Google Scholar
• Mukherjee K. L., Boohar J., Wentland D., Ansfield F. J., Heidelberger C. Studies on fluorinated pyrimidines: XVI. Metabolism of 5-fluorouracil-14C and 5-fluoro-2′-deoxyuridine-2-14C in cancer patients. Cancer Research 1963; 23: 49–54
   Web of Science ®Google Scholar
• Müller M., Meister N., Moor H. Freezing in a propane jet and its application in freeze-fracturing. Mikroskopie (Wien) 1980; 36: 129–140
   PubMedGoogle Scholar
• Myers C. E. The pharmacology of fluoropyrimidines. Pharmacological Reviews 1981; 33: 1–15
   PubMed Web of Science ®Google Scholar
• Parker R. J., Hartmann K. D., Sieber S. M. Lymphatic absorption and tissue disposition of liposome-entrapped 14C-adriamycin following intraperitoneal admini stration to rats. Cancer Research 1981; 41: 1311–1317
   PubMed Web of Science ®Google Scholar
• Poste G., Kirsh R., Bugelski P. Liposomes as drug delivery system in cancer therapy. Novel Approaches to Cancer Chemotherapy, P. S. Sunkara. Academic Press, New York 1984; 165–230
   Google Scholar
• Roobol C., DeDobbeleer G. B. E., Bernheim J. L. 5-Fluorouracil and 5-fluoro 2′-deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukemia. British Journal of Cancer 1984; 49: 739–744
   Google Scholar
• Rubas W., Supersaxo A., Weder H. G., Hartmann H. R., Hengartner H., Schott H., Schwendener R. A. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. International Journal of Cancer 1986; 37: 149–154
   PubMed Web of Science ®Google Scholar
• Schabel F. M., Griswold D. P., Corbett T. H., Laster W. R., Mayo J. G., Lloyd H. H. Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated potential clinical utility for treatment of advanced solid tumors of man. Methods in Cancer Research, Vol. XVIII, Cancer Drug Development, V. T. DeVita, H. Busch. Academic Press, New York 1979; 3–51, Part B
   Google Scholar
• Schwendener R. A., Supersaxo A., Rubas W., Weder H. G., Hartmann H. R., Schott H., Ziegler A., Hengartner H. 5′-O-Palmitoyl- and 3′,5′-O-dipalmitoyl 5-fluoro-2′-deoxyuridine—Novel lipophilic analogues of 5-fluoro-2′-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results. Biochemical and Biophysical Research Communications 1985; 126: 660–666
   PubMed Web of Science ®Google Scholar
• Sculier J. P., Coune A., Brassine C., Laduron C., Atassi G., Ruysschaert J. M., Frühling J. Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. Journal of Clinical Oncology 1986; 4: 789–797
   PubMed Web of Science ®Google Scholar
• Simmons S. P., Kramer P. A. Liposomal entrapment of floxuridine. Journal of Pharmaceutical Sciences 1977; 66: 984–986
   PubMed Web of Science ®Google Scholar
• Yoshihara E., Nakae T. Cytolytic activity of liposomes containing stearylamine. Biochimica et Biophysica Acta 1986; 854: 93–101
   PubMed Web of Science ®Google Scholar